Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on January 19th for the FORTIS Ph 1/2 clinical trial evaluating the safety, tolerability and efficacy of investigational AT845 in adults with late-onset Pompe disease (LOPD). Following the clinical hold lift, Astellas is working on completing the clinical and regulatory activities necessary to resume dosing in the FORTIS clinical trial.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,688 JPY | +1.99% |
|
+3.56% | +0.12% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.12% | 18.71B | |
+61.53% | 848B | |
+33.88% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+11.33% | 234B | |
+15.41% | 225B | |
+15.67% | 179B | |
+2.47% | 167B |
- Stock Market
- Equities
- 4503 Stock
- News Astellas Pharma Inc.
- Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease